Tools for mRESVIA® (Respiratory Syncytial Virus Vaccine)

Most payers, including Medicare Part D, process claims for mRESVIA under the pharmacy benefit. Some payers, including Medicaid and commercial, may allow access in an office setting and process under the medical benefit.

RSV = respiratory syncytial virus.

Indication and Important Safety Information

Indication

mRESVIA® (Respiratory Syncytial Virus Vaccine) is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.

Important Safety Information

Contraindications

Do not administer mRESVIA to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of mRESVIA.

Warnings and Precautions

Management of Acute Allergic Reactions: Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of mRESVIA.
Syncope: Syncope (fainting) may occur in association with administration of injectable vaccines, including mRESVIA. Procedures should be in place to avoid injury from fainting.
Altered Immunocompetence: Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to mRESVIA.

Adverse Reactions

In a clinical trial, the most commonly reported (≥10%) adverse reactions were injection-site pain (55.9%), fatigue (30.8%), headache (26.7%), myalgia (25.6%), arthralgia (21.7%), axillary (underarm) swelling or tenderness (15.2%) and chills (11.6%).

To report suspected adverse reactions, contact ModernaTX, Inc. at 1-866-663-3762 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please click for mRESVIA Full Prescribing Information.

References

mRESVIA Prescribing Information. ModernaTX, Inc.
AREXVY Prescribing Information. GlaxoSmithKline Biologics SA.
ABRYSVO Product Information. Pfizer Inc.

For Colorado and Connecticut price disclosure, please visit https://modernadirect.com/wac-disclosure

Stay up to date

Receive the latest information about mRESVIA and all the products in the Moderna pipeline.

By submitting your information, you agree to Moderna's Terms and Conditions. You also acknowledge that your information will be processed in accordance with Moderna's Privacy Statement. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.